Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Lanicemine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 1.00 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 1.00 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 1.00 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 1.00 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 1.00 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 1.00 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 1.00 |
| ▸ | PTPRA | P18433 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanicemine SCHEMBL29379976 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL1422817 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL30415652 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL13557819 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL18094971 | 0.98 | GRIN2D (0.96) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL31444739 | 0.98 | GRIN2D (0.96) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL6021911 | 0.98 | GRIN2D (0.96) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL6021910 | 0.98 | GRIN2D (0.96) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL13517622 | 0.98 | GRIN2D (0.96) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Lanicemine SCHEMBL8779477 | 0.87 | GRIN2D (0.77) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115836052-A | Topical formulations of (1S) -1-phenyl-2-pyridin-2-ylethylamine | 拜尔哈文制药股份有限公司 | 2023-03-21 | — | — | CN | claimed |
| EP-3564234-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | claimed |
| CN-105683180-B | NMDA antagonist prodrugs | 阿斯利康(瑞典)有限公司 | 2020-01-21 | — | — | CN | claimed |
| EP-3066091-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | claimed |
| EP-2791352-A1 | GABR-A2 DIAGNOSTIC | Astrazeneca AB (SE) | 2014-10-22 | — | — | EP | claimed |
| WO-2013088135-A1 | GABR-A2 DIAGNOSTIC | ASTRAZENECA AB (SE) | 2013-06-20 | — | — | WO | claimed |
| US-7799337-B2 | For inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation; administering to patient using intranasal drug delivery device | BHL PATENT HOLDINGS LLC | 2010-09-21 | — | — | US | claimed |
| WO-2007017652-A2 | ARYLAKYLAMINES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| JP-3120810-B2 | — | — | 2000-12-25 | — | — | JP | claimed |
| WO-2000063174-A1 | NOVEL PROCESS | ASTRAZENECA AB (SE) | 2000-10-26 | — | — | WO | claimed |
| EP-0691958-B1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE BENZOATE AND ITS USE AS A MEDICAMENT | ASTRA AB (SE) | 1997-08-13 | — | — | EP | claimed |
| US-5605916-A | Arylalkyl-amines having anticonvulsant and neuroprotective properties | ASTRA AB (SE) | 1997-02-25 | — | — | US | claimed |
| EP-0356035-B1 | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties | ASTRA AB (SE) | 1996-03-13 | — | — | EP | claimed |
| EP-0691957-A1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE (S)-MALATE AND ITS USE AS A MEDICAMENT | ASTRA AB (SE) | 1996-01-17 | — | — | EP | claimed |
| WO-1995031986-A1 | COMBINATION PRODUCT OF DICHLOROACETIC ACID AND AN NMDA ANTAGONIST | ASTRA AKTIEBOLAG (SE) | 1995-11-30 | — | — | WO | claimed |
| US-5430044-A | Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties | FISONS CORPORATION (GB) | 1995-07-04 | — | — | US | claimed |
| EP-0648745-A1 | Arylalkylamine having anticonvulsant and neuroprotective properties | Astra Aktiebolag (SE) | 1995-04-19 | — | — | EP | claimed |
| EP-0633879-A1 | ENANTIOMERIC 1-PHENYL-2-(2-PYRIDINYL)ETHYLAMINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Astra Aktiebolag (SE) | 1995-01-18 | — | — | EP | claimed |
| WO-1994022831-A1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE (S)-MALATE AND ITS USE AS A MEDICAMENT | ASTRA AKTIEBOLAG (SE) | 1994-10-13 | — | — | WO | claimed |
| WO-1993020052-A1 | ENANTIOMERIC 1-PHENYL-2-(2-PYRIDINYL)ETHYLAMINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | FISONS CORPORATION (US) | 1993-10-14 | — | — | WO | claimed |